MX2019001285A - Composicion de cannabis. - Google Patents

Composicion de cannabis.

Info

Publication number
MX2019001285A
MX2019001285A MX2019001285A MX2019001285A MX2019001285A MX 2019001285 A MX2019001285 A MX 2019001285A MX 2019001285 A MX2019001285 A MX 2019001285A MX 2019001285 A MX2019001285 A MX 2019001285A MX 2019001285 A MX2019001285 A MX 2019001285A
Authority
MX
Mexico
Prior art keywords
treating
relates
sleep disorder
cannabis composition
cannabis extract
Prior art date
Application number
MX2019001285A
Other languages
English (en)
Inventor
Karelis Harry
Gordon Mara
Smith Stewart
Washer Stewart
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019001285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of MX2019001285A publication Critical patent/MX2019001285A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un método para tratar un trastorno del sueño. Preferentemente, la invención se refiere a un método para tratar un trastorno del sueño que comprende la etapa de administrar una composición farmacéutica que comprende un extracto de Cannabis y opcionalmente uno o más portadores, diluyentes, adyuvantes, excipientes farmacéuticamente aceptables o cualquier combinación de estos, el extracto de Cannabis que comprende una fracción de terpeno que comprende limoneno en una cantidad de al menos aproximadamente 5.4 % en peso de la fracción de terpeno.
MX2019001285A 2016-08-03 2017-08-03 Composicion de cannabis. MX2019001285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
MX2019001285A true MX2019001285A (es) 2019-06-13

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001285A MX2019001285A (es) 2016-08-03 2017-08-03 Composicion de cannabis.

Country Status (15)

Country Link
US (2) US11779562B2 (es)
EP (1) EP3493798A4 (es)
JP (1) JP2019523283A (es)
KR (2) KR20190035791A (es)
CN (1) CN109843287A (es)
AU (4) AU2017307643B2 (es)
BR (1) BR112019001852A2 (es)
CA (1) CA3031810A1 (es)
CL (1) CL2019000270A1 (es)
CO (1) CO2019001044A2 (es)
IL (2) IL264461B1 (es)
MX (1) MX2019001285A (es)
PE (1) PE20200726A1 (es)
SG (1) SG11201900665VA (es)
WO (1) WO2018023163A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
BR112019020554A2 (pt) * 2017-03-30 2020-04-28 Ojai Energetics Pbc métodos e composições para melhorar as condições de saúde
AU2018100837B4 (en) * 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
CA3103938A1 (en) * 2018-06-15 2019-12-19 California Cannabinoids Compositions and methods for treatment of narcolepsy and related disorders
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
WO2020168073A1 (en) * 2019-02-13 2020-08-20 Caras Jim Composition comprising hydrolyzed collagen and cannabidiol and use thereof
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400320B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 A2a 수용체 작용제
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
JP2015515977A (ja) 2012-05-03 2015-06-04 エコ・ファーマシューティカルズ・ビー.ブイ.Echo Pharmaceuticals B.V. Δ9−テトラヒドロカンナビノールを含む大麻草単離物及びこのような単離物を製造するための方法
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2014159688A1 (en) 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
MX2015013202A (es) * 2013-03-15 2016-04-07 Biotech Inst Llc Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
DK3062606T3 (da) * 2013-10-29 2019-06-24 Biotech Inst Llc Forædling, fremstilling, forarbejdning og anvendelse af speciel cannabis
WO2015068052A2 (en) 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
WO2015200049A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
EP3209312A1 (en) * 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
EA201791299A1 (ru) 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
US10406186B2 (en) 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US20190307719A1 (en) 2016-08-03 2019-10-10 Zelda Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
AU2017307643A1 (en) 2018-07-05
EP3493798A4 (en) 2020-05-06
AU2018100923C4 (en) 2019-10-31
IL296008B1 (en) 2024-05-01
EP3493798A1 (en) 2019-06-12
AU2021240297A1 (en) 2021-10-28
CO2019001044A2 (es) 2019-04-30
AU2017307643B2 (en) 2019-07-25
BR112019001852A2 (pt) 2019-05-07
US20220347155A1 (en) 2022-11-03
CL2019000270A1 (es) 2019-10-04
WO2018023163A1 (en) 2018-02-08
US20230414559A1 (en) 2023-12-28
KR20190035791A (ko) 2019-04-03
CA3031810A1 (en) 2018-02-08
IL296008A (en) 2022-10-01
AU2021240297B2 (en) 2023-08-24
AU2018100923B4 (en) 2018-09-27
AU2019253841A1 (en) 2019-11-14
SG11201900665VA (en) 2019-02-27
AU2019253841B2 (en) 2021-07-01
JP2019523283A (ja) 2019-08-22
KR20210013645A (ko) 2021-02-04
US11779562B2 (en) 2023-10-10
PE20200726A1 (es) 2020-07-21
CN109843287A (zh) 2019-06-04
IL264461A (en) 2019-02-28
IL264461B1 (en) 2024-05-01
AU2018100923A4 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2019001285A (es) Composicion de cannabis.
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
MX2019001286A (es) Composicion de cannabis.
CL2019000268A1 (es) Composición de cannabis.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IN2013MU01696A (es)
IN2013MU03583A (es)
NZ754020A (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
SG10201908500UA (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
MY197685A (en) Use of a pharmaceutical composition in the manufacture of a medicament for treating a malignant pleural effusions
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2022003945A (es) Metodo para tratar vih con cabotegravir y rilpivirina.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
MX2020005310A (es) Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
MX2019001320A (es) Composicion y uso de un peptido.